NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour purchased another 70,000 shares as the company prepares for FDA discussions on NEO100. The purchases totaled approximately $294,500, bringing his November 5–11 purchases to 150,000 shares costing approximately $563,582. His reported direct holdings reached 3,333,000 shares.
The FDA granted a Type B End-of-Phase meeting for early January 2027. NeOnc plans to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma and seek agreement on its proposed Phase 3 trial. Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data are scheduled for presentation November 13; a NEO212 FDA meeting follows November 17. Short interest reached approximately 921,000 shares on October 30, versus 876,682 on October 15.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA granted a Type B End-of-Phase meeting for early January 2027 to discuss NEO100 development.
- Minor pointCEO purchases totaled 150,000 shares for approximately $563,582 across November 5–11, increasing his ownership.
- Minor point. Forward-looking: it has not happened yet and may not happen.NEO100 and NEO212 clinical updates are scheduled for presentation November 13.
- Minor point. Forward-looking: it has not happened yet and may not happen.NEO212 FDA End-of-Phase 1 meeting is scheduled for November 17 to discuss proposed Phase 2 development.
- Minor pointRoth MKM reaffirmed its Buy rating and $20 price target.
Negative
- Moderate pointNEO100’s potential accelerated approval pathway requires FDA feedback; agreement on the proposed Phase 3 trial remains pending.
- Minor pointShort interest increased to approximately 921,000 shares on October 30 from 876,682 on October 15.
Key Figures
- Latest shares purchased
- 70,000 shares
- CEO open-market purchases
- Latest purchase value
- approximately $294,500
- Latest transactions
- Recent purchases
- 150,000 shares
- Recent CEO purchases
- Combined purchase amount
- approximately $563,582
- Purchases across November 5–11
- FDA meeting timing
- early January 2027
- Type B End-of-Phase meeting for NEO100
Previous Clinical trial Reports
-
NEO100 met its primary endpoint, reporting six-month progression-free survival of 48.9%.
-
Positive NEO100 Phase 2a data accompanied plans for a Type B FDA pathway meeting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
type b end-of-phase meeting regulatory
accelerated approval regulatory
overall survival medical
idh-mutant medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Recent purchases total 150,000 shares as NeOnc prepares to discuss potential accelerated approval and a Phase 3 confirmatory trial for NEO100
DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com)— NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares in the open market, bringing his recent purchases to 150,000 shares as the company approaches important clinical and regulatory milestones.
The latest transactions represent approximately
Our bullish interpretation: the CEO continues putting personal capital behind his conviction as NeOnc’s development story advances.
The CEO Keeps Buying Higher
The latest filing summary details three purchases:
| Transaction date | Shares purchased | Reported price | |
| November 10 | 50,000 | ||
| November 11 | 10,000 | ||
| November 11 | 10,000 | ||
| Total | 70,000 | Approximately | |
The transactions increased Heshmatpour’s reported direct holdings to 3,333,000 shares, separate from his indirectly held positions.
NeOnc previously announced purchases of 80,000 shares across November 5, 6 and 9, totaling approximately
The progression stands out. Earlier purchases came in the low-to-mid
These open-market purchases increase his ownership as investors evaluate the company’s next milestones. Roth MKM also recently reaffirmed its Buy rating and
FDA Meeting Puts Phase 3 and Accelerated Approval on the Agenda
On November 11, NeOnc announced that the FDA granted a Type B End-of-Phase meeting scheduled for early January 2027 to discuss a potential accelerated approval pathway for intranasal NEO100.
NeOnc intends to seek feedback on whether its clinical and nonclinical evidence could support an accelerated approval application for recurrent or progressive IDH-mutant grade 4 astrocytoma.
The company will also seek agreement on NEO100-012, a proposed randomized Phase 3 trial comparing NEO100 with investigator-selected standard-of-care chemotherapy. Overall survival would be the primary endpoint, with the study intended to provide registrational and confirmatory evidence.
NeOnc now has an FDA discussion scheduled around a potential approval pathway and the design of a Phase 3 trial. Positive Phase 2a findings provide the foundation for that discussion and give investors a defined next step to follow.
Two Programs. Several Dates to Watch.
The January meeting adds to an already active calendar:
- November 13: Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data are scheduled for presentation at the Society for Neuro-Oncology Annual Meeting.
- November 17: NeOnc’s FDA End-of-Phase 1 meeting for NEO212 is scheduled to address proposed Phase 2 development and next steps.
- Early January 2027: The newly announced NEO100 meeting will address its potential accelerated approval pathway and proposed Phase 3 trial.
Two investigational drugs, upcoming scientific presentations, separate FDA discussions and continued CEO buying give investors several developments to watch.
A Larger Short Position Adds Potential Fuel
The latest short-interest update puts NTHI at approximately 921,000 shares short as of October 30, compared with 876,682 on October 15.
That represents an increase of roughly 44,000 shares before the stock’s recent advance through
Updated NEO100 data and NEO212 Phase 1 findings are scheduled for presentation at this week’s Society for Neuro-Oncology annual meeting.
About InvestorsTape.com
At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.
Contact
benh@investorstape.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.
General Disclaimer:
InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.
This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities. This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will NeOnc meet with the FDA about NEO100 accelerated approval?
The FDA meeting is scheduled for early January 2027. NeOnc intends to seek feedback on whether its clinical and nonclinical evidence could support an accelerated approval application for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma.
What trial design is NeOnc proposing for NEO100 Phase 3?
NeOnc proposes NEO100-012 as a randomized Phase 3 trial comparing NEO100 with investigator-selected standard-of-care chemotherapy. Overall survival would be the primary endpoint—the main outcome measured—and the study is intended to provide evidence for registration and confirmation.